![]() 胆管がん治療薬-世界市場シェア・ランキング、全体売上高・需要予測 2025-2031Cholangiocarcinoma Treatment Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 胆管がん治療薬の世界市場は、2024年には2億6400万米ドル規模と推定され、2031年には3億6500万米ドルに再調整され、予測期間2025-2031年のCAGRは4.8%と予測されている。 胆管癌治療薬は、胆管に発生する癌の一... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー胆管がん治療薬の世界市場は、2024年には2億6400万米ドル規模と推定され、2031年には3億6500万米ドルに再調整され、予測期間2025-2031年のCAGRは4.8%と予測されている。胆管癌治療薬は、胆管に発生する癌の一種である胆管癌の管理に使用される薬剤および治療薬である。治療薬の選択は、がんの病期、患者の全身状態、その他の個々の要因によって異なる。胆管がんの治療には、手術、化学療法、放射線療法、標的療法、そして場合によっては免疫療法が組み合わされる。 世界の医薬品市場は、2022年には1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行は、ワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 本レポートは、胆管癌治療薬の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の胆管癌治療薬の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。 胆管がん治療薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、胆管癌治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 デルキャス・システムズ 協和発酵キリン サノフィ ジョンソン・エンド・ジョンソンサービス ノバルティスAG マイランNV テバ・ファーマシューティカルズ・インダストリーズ F・ホフマン・ラ・ロシュAG フレゼニウス・カビAG アコードヘルスケア ブリストル・マイヤーズ スクイブ・カンパニー セルジーン・コーポレーション ファイザー イーライリリー・アンド・カンパニー タイプ別セグメント ゲムシタビン カペシタビン オキサリプラチン 用途別セグメント 病院 専門クリニック その他 地域別 北米 米国 カナダ アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア その他のアジア太平洋地域 ヨーロッパ ドイツ フランス 英国 イタリア オランダ 北欧諸国 その他のヨーロッパ ラテンアメリカ メキシコ ブラジル その他のラテンアメリカ 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 その他のMEA 各章の概要 第1章: レポートのスコープ、世界の総市場規模を紹介します。また、市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章:胆管癌治療薬企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章:地域レベルでの胆管がん治療薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章:胆管癌治療薬の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章:産業の上流と下流を含む産業チェーンの分析。 第9章:結論 目次1 Market Overview1.1 Cholangiocarcinoma Treatment Drugs Product Introduction 1.2 Global Cholangiocarcinoma Treatment Drugs Market Size Forecast (2020-2031) 1.3 Cholangiocarcinoma Treatment Drugs Market Trends & Drivers 1.3.1 Cholangiocarcinoma Treatment Drugs Industry Trends 1.3.2 Cholangiocarcinoma Treatment Drugs Market Drivers & Opportunity 1.3.3 Cholangiocarcinoma Treatment Drugs Market Challenges 1.3.4 Cholangiocarcinoma Treatment Drugs Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Cholangiocarcinoma Treatment Drugs Players Revenue Ranking (2024) 2.2 Global Cholangiocarcinoma Treatment Drugs Revenue by Company (2020-2025) 2.3 Key Companies Cholangiocarcinoma Treatment Drugs Manufacturing Base Distribution and Headquarters 2.4 Key Companies Cholangiocarcinoma Treatment Drugs Product Offered 2.5 Key Companies Time to Begin Mass Production of Cholangiocarcinoma Treatment Drugs 2.6 Cholangiocarcinoma Treatment Drugs Market Competitive Analysis 2.6.1 Cholangiocarcinoma Treatment Drugs Market Concentration Rate (2020-2025) 2.6.2 Global 5 and 10 Largest Companies by Cholangiocarcinoma Treatment Drugs Revenue in 2024 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Treatment Drugs as of 2024) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Gemcitabine 3.1.2 Capecitabine 3.1.3 Oxaliplatin 3.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Type 3.2.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Type (2020-2031) 3.2.3 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Type (%) (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Specialty Clinic 4.1.3 Others 4.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Application 4.2.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Application (2020-2031) 4.2.3 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Application (%) (2020-2031) 5 Segmentation by Region 5.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region 5.1.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (2020-2025) 5.1.3 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (2026-2031) 5.1.4 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (%), (2020-2031) 5.2 North America 5.2.1 North America Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.2.2 North America Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.3 Europe 5.3.1 Europe Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.3.2 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.4 Asia Pacific 5.4.1 Asia Pacific Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.4.2 Asia Pacific Cholangiocarcinoma Treatment Drugs Sales Value by Region (%), 2024 VS 2031 5.5 South America 5.5.1 South America Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.5.2 South America Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.6 Middle East & Africa 5.6.1 Middle East & Africa Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.6.2 Middle East & Africa Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Cholangiocarcinoma Treatment Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.3 United States 6.3.1 United States Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.3.2 United States Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.4.2 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.5.2 China Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.5.3 China Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.6.2 Japan Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.7.2 South Korea Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.8.2 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.9.2 India Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.9.3 India Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Delcath Systems 7.1.1 Delcath Systems Profile 7.1.2 Delcath Systems Main Business 7.1.3 Delcath Systems Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.1.4 Delcath Systems Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.1.5 Delcath Systems Recent Developments 7.2 Kyowa Hakko Kirin 7.2.1 Kyowa Hakko Kirin Profile 7.2.2 Kyowa Hakko Kirin Main Business 7.2.3 Kyowa Hakko Kirin Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.2.4 Kyowa Hakko Kirin Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.2.5 Kyowa Hakko Kirin Recent Developments 7.3 Sanofi 7.3.1 Sanofi Profile 7.3.2 Sanofi Main Business 7.3.3 Sanofi Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.3.4 Sanofi Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.3.5 Sanofi Recent Developments 7.4 Johnson & Johnson Services 7.4.1 Johnson & Johnson Services Profile 7.4.2 Johnson & Johnson Services Main Business 7.4.3 Johnson & Johnson Services Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.4.4 Johnson & Johnson Services Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.4.5 Johnson & Johnson Services Recent Developments 7.5 Novartis AG 7.5.1 Novartis AG Profile 7.5.2 Novartis AG Main Business 7.5.3 Novartis AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.5.4 Novartis AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.5.5 Novartis AG Recent Developments 7.6 Mylan NV 7.6.1 Mylan NV Profile 7.6.2 Mylan NV Main Business 7.6.3 Mylan NV Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.6.4 Mylan NV Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.6.5 Mylan NV Recent Developments 7.7 Teva Pharmaceuticals Industries 7.7.1 Teva Pharmaceuticals Industries Profile 7.7.2 Teva Pharmaceuticals Industries Main Business 7.7.3 Teva Pharmaceuticals Industries Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.7.4 Teva Pharmaceuticals Industries Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.7.5 Teva Pharmaceuticals Industries Recent Developments 7.8 F. Hoffman-La Roche AG 7.8.1 F. Hoffman-La Roche AG Profile 7.8.2 F. Hoffman-La Roche AG Main Business 7.8.3 F. Hoffman-La Roche AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.8.4 F. Hoffman-La Roche AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.8.5 F. Hoffman-La Roche AG Recent Developments 7.9 Fresenius Kabi AG 7.9.1 Fresenius Kabi AG Profile 7.9.2 Fresenius Kabi AG Main Business 7.9.3 Fresenius Kabi AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.9.4 Fresenius Kabi AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.9.5 Fresenius Kabi AG Recent Developments 7.10 Accord Healthcare 7.10.1 Accord Healthcare Profile 7.10.2 Accord Healthcare Main Business 7.10.3 Accord Healthcare Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.10.4 Accord Healthcare Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.10.5 Accord Healthcare Recent Developments 7.11 Bristol-Myers Squibb Company 7.11.1 Bristol-Myers Squibb Company Profile 7.11.2 Bristol-Myers Squibb Company Main Business 7.11.3 Bristol-Myers Squibb Company Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.11.4 Bristol-Myers Squibb Company Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.11.5 Bristol-Myers Squibb Company Recent Developments 7.12 Celgene Corporation 7.12.1 Celgene Corporation Profile 7.12.2 Celgene Corporation Main Business 7.12.3 Celgene Corporation Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.12.4 Celgene Corporation Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.12.5 Celgene Corporation Recent Developments 7.13 Pfizer 7.13.1 Pfizer Profile 7.13.2 Pfizer Main Business 7.13.3 Pfizer Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.13.4 Pfizer Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.13.5 Pfizer Recent Developments 7.14 Eli Lilly and Company 7.14.1 Eli Lilly and Company Profile 7.14.2 Eli Lilly and Company Main Business 7.14.3 Eli Lilly and Company Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.14.4 Eli Lilly and Company Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.14.5 Eli Lilly and Company Recent Developments 8 Industry Chain Analysis 8.1 Cholangiocarcinoma Treatment Drugs Industrial Chain 8.2 Cholangiocarcinoma Treatment Drugs Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Cholangiocarcinoma Treatment Drugs Sales Model 8.5.2 Sales Channel 8.5.3 Cholangiocarcinoma Treatment Drugs Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Cholangiocarcinoma Treatment Drugs was estimated to be worth US$ 264 million in 2024 and is forecast to a readjusted size of US$ 365 million by 2031 with a CAGR of 4.8% during the forecast period 2025-2031. Table of Contents1 Market Overview1.1 Cholangiocarcinoma Treatment Drugs Product Introduction 1.2 Global Cholangiocarcinoma Treatment Drugs Market Size Forecast (2020-2031) 1.3 Cholangiocarcinoma Treatment Drugs Market Trends & Drivers 1.3.1 Cholangiocarcinoma Treatment Drugs Industry Trends 1.3.2 Cholangiocarcinoma Treatment Drugs Market Drivers & Opportunity 1.3.3 Cholangiocarcinoma Treatment Drugs Market Challenges 1.3.4 Cholangiocarcinoma Treatment Drugs Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Cholangiocarcinoma Treatment Drugs Players Revenue Ranking (2024) 2.2 Global Cholangiocarcinoma Treatment Drugs Revenue by Company (2020-2025) 2.3 Key Companies Cholangiocarcinoma Treatment Drugs Manufacturing Base Distribution and Headquarters 2.4 Key Companies Cholangiocarcinoma Treatment Drugs Product Offered 2.5 Key Companies Time to Begin Mass Production of Cholangiocarcinoma Treatment Drugs 2.6 Cholangiocarcinoma Treatment Drugs Market Competitive Analysis 2.6.1 Cholangiocarcinoma Treatment Drugs Market Concentration Rate (2020-2025) 2.6.2 Global 5 and 10 Largest Companies by Cholangiocarcinoma Treatment Drugs Revenue in 2024 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Treatment Drugs as of 2024) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Gemcitabine 3.1.2 Capecitabine 3.1.3 Oxaliplatin 3.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Type 3.2.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Type (2020-2031) 3.2.3 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Type (%) (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Specialty Clinic 4.1.3 Others 4.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Application 4.2.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Application (2020-2031) 4.2.3 Global Cholangiocarcinoma Treatment Drugs Sales Value, by Application (%) (2020-2031) 5 Segmentation by Region 5.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region 5.1.1 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (2020-2025) 5.1.3 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (2026-2031) 5.1.4 Global Cholangiocarcinoma Treatment Drugs Sales Value by Region (%), (2020-2031) 5.2 North America 5.2.1 North America Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.2.2 North America Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.3 Europe 5.3.1 Europe Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.3.2 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.4 Asia Pacific 5.4.1 Asia Pacific Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.4.2 Asia Pacific Cholangiocarcinoma Treatment Drugs Sales Value by Region (%), 2024 VS 2031 5.5 South America 5.5.1 South America Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.5.2 South America Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 5.6 Middle East & Africa 5.6.1 Middle East & Africa Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 5.6.2 Middle East & Africa Cholangiocarcinoma Treatment Drugs Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Cholangiocarcinoma Treatment Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.3 United States 6.3.1 United States Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.3.2 United States Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.4.2 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.5.2 China Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.5.3 China Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.6.2 Japan Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.7.2 South Korea Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.8.2 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Cholangiocarcinoma Treatment Drugs Sales Value, 2020-2031 6.9.2 India Cholangiocarcinoma Treatment Drugs Sales Value by Type (%), 2024 VS 2031 6.9.3 India Cholangiocarcinoma Treatment Drugs Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Delcath Systems 7.1.1 Delcath Systems Profile 7.1.2 Delcath Systems Main Business 7.1.3 Delcath Systems Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.1.4 Delcath Systems Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.1.5 Delcath Systems Recent Developments 7.2 Kyowa Hakko Kirin 7.2.1 Kyowa Hakko Kirin Profile 7.2.2 Kyowa Hakko Kirin Main Business 7.2.3 Kyowa Hakko Kirin Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.2.4 Kyowa Hakko Kirin Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.2.5 Kyowa Hakko Kirin Recent Developments 7.3 Sanofi 7.3.1 Sanofi Profile 7.3.2 Sanofi Main Business 7.3.3 Sanofi Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.3.4 Sanofi Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.3.5 Sanofi Recent Developments 7.4 Johnson & Johnson Services 7.4.1 Johnson & Johnson Services Profile 7.4.2 Johnson & Johnson Services Main Business 7.4.3 Johnson & Johnson Services Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.4.4 Johnson & Johnson Services Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.4.5 Johnson & Johnson Services Recent Developments 7.5 Novartis AG 7.5.1 Novartis AG Profile 7.5.2 Novartis AG Main Business 7.5.3 Novartis AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.5.4 Novartis AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.5.5 Novartis AG Recent Developments 7.6 Mylan NV 7.6.1 Mylan NV Profile 7.6.2 Mylan NV Main Business 7.6.3 Mylan NV Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.6.4 Mylan NV Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.6.5 Mylan NV Recent Developments 7.7 Teva Pharmaceuticals Industries 7.7.1 Teva Pharmaceuticals Industries Profile 7.7.2 Teva Pharmaceuticals Industries Main Business 7.7.3 Teva Pharmaceuticals Industries Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.7.4 Teva Pharmaceuticals Industries Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.7.5 Teva Pharmaceuticals Industries Recent Developments 7.8 F. Hoffman-La Roche AG 7.8.1 F. Hoffman-La Roche AG Profile 7.8.2 F. Hoffman-La Roche AG Main Business 7.8.3 F. Hoffman-La Roche AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.8.4 F. Hoffman-La Roche AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.8.5 F. Hoffman-La Roche AG Recent Developments 7.9 Fresenius Kabi AG 7.9.1 Fresenius Kabi AG Profile 7.9.2 Fresenius Kabi AG Main Business 7.9.3 Fresenius Kabi AG Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.9.4 Fresenius Kabi AG Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.9.5 Fresenius Kabi AG Recent Developments 7.10 Accord Healthcare 7.10.1 Accord Healthcare Profile 7.10.2 Accord Healthcare Main Business 7.10.3 Accord Healthcare Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.10.4 Accord Healthcare Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.10.5 Accord Healthcare Recent Developments 7.11 Bristol-Myers Squibb Company 7.11.1 Bristol-Myers Squibb Company Profile 7.11.2 Bristol-Myers Squibb Company Main Business 7.11.3 Bristol-Myers Squibb Company Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.11.4 Bristol-Myers Squibb Company Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.11.5 Bristol-Myers Squibb Company Recent Developments 7.12 Celgene Corporation 7.12.1 Celgene Corporation Profile 7.12.2 Celgene Corporation Main Business 7.12.3 Celgene Corporation Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.12.4 Celgene Corporation Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.12.5 Celgene Corporation Recent Developments 7.13 Pfizer 7.13.1 Pfizer Profile 7.13.2 Pfizer Main Business 7.13.3 Pfizer Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.13.4 Pfizer Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.13.5 Pfizer Recent Developments 7.14 Eli Lilly and Company 7.14.1 Eli Lilly and Company Profile 7.14.2 Eli Lilly and Company Main Business 7.14.3 Eli Lilly and Company Cholangiocarcinoma Treatment Drugs Products, Services and Solutions 7.14.4 Eli Lilly and Company Cholangiocarcinoma Treatment Drugs Revenue (US$ Million) & (2020-2025) 7.14.5 Eli Lilly and Company Recent Developments 8 Industry Chain Analysis 8.1 Cholangiocarcinoma Treatment Drugs Industrial Chain 8.2 Cholangiocarcinoma Treatment Drugs Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Cholangiocarcinoma Treatment Drugs Sales Model 8.5.2 Sales Channel 8.5.3 Cholangiocarcinoma Treatment Drugs Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(demand)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|